Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer
This phase II trial studies the side effects of erlotinib hydrochloride (350 mg po once
weekly for up to 6 months) and how well it works in reducing duodenal polyp burden in
patients with familial adenomatous polyposis at risk of developing colon cancer. Erlotinib
hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for
cell growth.
Intervention
Erlotinib, Erlotinib Hydrochloride
Condition
Attenuated Familial Adenomatous Polyposis, Familial Adenomatous Polyposis
Investigators
Niloy J Samadder